Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-17

Clinical Trial Update: Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer [Phase 2]

View source ↗

Summary

This update summarizes a completed Phase 2 safety and toxicity study of sorafenib in patients with renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED